secwatch.observer — SEC 8-K summary
======================================

Issuer:     Serina Therapeutics, Inc. (SER)
CIK:        0001708599
Form:       8-K
Filed at:   2024-12-26T23:59:59+00:00
Accession:  0001708599-24-000033
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 2.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Serina sells UniverXome subsidiary to Juvenescence affiliate for $10 plus assumption of ~$11.2M debt
--------------------------------------------------------------------------------

- Sold UniverXome (holding ReCyte and Reverse Bio) to JuvVentures for $10 and assumption of ~$11.2M secured debt.
- Juvenescence is Serina's largest shareholder; Special Committee approved with third-party valuation.
- UniverXome owned 94.8% of ReCyte and 100% of Reverse Bio, legacy AgeX assets from pre-merger.
- Intellectual property transfer not perfected; buyer bears future filing costs.
- Company makes no warranty beyond express representations; assets fully encumbered by pre-existing debt to buyer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1708599/000170859924000033/0001708599-24-000033-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1708599/000170859924000033/ser-20241223.htm
  HTML page:      https://secwatch.observer/filing/0001708599-24-000033

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer